<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213639</url>
  </required_header>
  <id_info>
    <org_study_id>ESOPE</org_study_id>
    <nct_id>NCT03213639</nct_id>
  </id_info>
  <brief_title>Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial)</brief_title>
  <official_title>Use of Esomeprazole in Treatment of Early Onset Preeclampsia:a Double Blind Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-eclampsia is one of the most serious complications of pregnancy affecting 3-8 % of&#xD;
      pregnancies worldwide. It is a multi-system disorder involving maternal vessels (causing&#xD;
      hypertension and endothelial dysfunction), the kidneys, the liver, the lungs, the&#xD;
      hematological system, the cardiovascular system and the feto-placental unit. In its most&#xD;
      severe form, it affects the brain, causing seizures (eclampsia), cerebro-vascular events and&#xD;
      even death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The key aspects in the pathophysiology of pre-eclampsia are placental oxidative stress (and&#xD;
      hypoxia), placental release of the anti-angiogenic factors Soluble Fms Like Tyrosine Kinase&#xD;
      -1 and soluble endoglin and maternal endothelial dysfunction. A drug that can counter these&#xD;
      pathological steps could be a strategy to treat pre-eclampsia.&#xD;
&#xD;
      If an affordable and safe treatment was available it could temporize the disease progression&#xD;
      of pre-eclampsia thereby delaying delivery to gain gestation. This could save the lives of&#xD;
      many infants and decrease the hospital burden caused by iatrogenic prematurity.&#xD;
&#xD;
      Currently, there are trials investigating the possible use of pravastatin to treat&#xD;
      pre-eclampsia, and to prevent it There are no other significant trials of orally available&#xD;
      small molecules to treat pre-eclampsia that we are aware of.&#xD;
&#xD;
      The Translational Obstetrics Group at Melbourne University has generated strong preclinical&#xD;
      evidence suggesting esomeprazole as one of the proton pump inhibitors may have potent actions&#xD;
      giving it significant potential as a treatment for pre-eclampsia&#xD;
&#xD;
      Proton pump inhibitors have been commonly used in pregnancy to treat gastroesophageal reflux&#xD;
      disorders and more serious gastrointestinal complications like Helicobacter pylori-infection,&#xD;
      peptic and duodenal ulcers and Zollinger-Ellison syndrome.&#xD;
&#xD;
      Esomeprazole counters three key steps in pre-eclampsia pathogenesis, by up-regulating heme&#xD;
      oxygenase-1 ( strongly decreasing the release of antiangiogenic factors Soluble Fms Like&#xD;
      Tyrosine Kinase -1 and soluble endoglin and quenching endothelial dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women who develop HELLP syndrome</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in serum level of sFlt-1 and endoglin before the start of treatment and at termination of pregnancy</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolongation of gestation measured from the time of enrollment to the time of delivery</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The side effects of the drugs</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take esomeprazole single dose of 40 mg orally once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will take an inert tablet similar in appearance, color and consistency</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40 mg Oral Tablet</intervention_name>
    <description>once daily oral tablets</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>once daily oral tablets</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>inert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age between 28 + 0 weeks and 31 + 6 weeks&#xD;
&#xD;
          -  Estimated fetal weight by ultrasound between 500 gm and 1800 gm (if gestation is not&#xD;
             certain).&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  The patient will be managed with expectant management.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is unable or unwilling to give consent&#xD;
&#xD;
          -  Established fetal compromise that necessitates delivery.&#xD;
&#xD;
          -  The presence of any of the following at presentation:&#xD;
&#xD;
               -  Eclampsia.&#xD;
&#xD;
               -  Severe hypertension.&#xD;
&#xD;
               -  Cerebrovascular event as an ischaemic or haemorrhagic stroke.&#xD;
&#xD;
               -  Renal impairment.&#xD;
&#xD;
               -  Signs of left ventricular failure which include pulmonary oedema.&#xD;
&#xD;
               -  Disseminated intravascular coagulation (DIC)&#xD;
&#xD;
               -  Haemolysis, elevated liver enzymes and low platelets (HELLP syndrome)&#xD;
&#xD;
               -  Fetal distress on cardiotocography&#xD;
&#xD;
          -  Contra-indications for expectant management of pre-eclampsia&#xD;
&#xD;
          -  Current use of a proton pump inhibitor&#xD;
&#xD;
          -  Contraindications to the use of a proton pump inhibitor&#xD;
&#xD;
          -  Previous hypersensitivity reaction to a proton pump inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Abbas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Cluver CA, Walker SP, Mol BW, Theron GB, Hall DR, Hiscock R, Hannan N, Tong S. Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open. 2015 Oct 28;5(10):e008211. doi: 10.1136/bmjopen-2015-008211.</citation>
    <PMID>26510725</PMID>
  </reference>
  <reference>
    <citation>Lagan√† AS, Favilli A, Triolo O, Granese R, Gerli S. Early serum markers of pre-eclampsia: are we stepping forward? J Matern Fetal Neonatal Med. 2016 Sep;29(18):3019-23. doi: 10.3109/14767058.2015.1113522. Epub 2015 Nov 23. Review.</citation>
    <PMID>26512423</PMID>
  </reference>
  <reference>
    <citation>Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 2008 Sep;199(3):266.e1-6. doi: 10.1016/j.ajog.2008.06.069.</citation>
    <PMID>18771978</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 8, 2017</study_first_submitted>
  <study_first_submitted_qc>July 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

